FAQs about Kesimpta
Kesimpta was approved in August 2020 for the treatment of adults with relapsing forms of MS. It can be prescribed for patients with clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. Ofatumumab had originally been approved in 2009, under the brand name Arzerra and under a different administration regimen, for patients with chronic lymphocytic leukemia.
Kesimpta may cause fetal harm, therefore the medication is not recommended for pregnant patients. Those who can become pregnant are advised to use birth control methods during treatment and for six months after stopping the therapy.
No known interactions exist between Kesimpta and alcohol. However, given that alcohol can interfere with some medications and disease symptoms, patients are advised to discuss this topic with their healthcare team.
Each person may react to a treatment in a different way. Patients are advised to discuss with their healthcare providers how can Kesimpta help in their particular case.
Hair loss and weight gain have not been reported in studies as side effects associated with Kesimpta. Patients are advised to talk with their healthcare team if they experience any such issues.